Skip to Content
Showing 1-1 of 1

Sorted By:

  • AEGIS II

    A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome)